Actively Recruiting
Studying Annexin A2 Levels on Monocytes in Adults with Primary Antiphospholipid Syndrome Using Flow Cytometry
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-11-19
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the role of Annexin A2 ANXA2 on circulating monocytes in people with primary antiphospholipid syndrome APS. APS is a condition involving abnormal blood clotting and immune system dysfunction. This study aims to understand how changes in ANXA2 expression on monocytes might contribute to the disease by affecting blood clot breakdown processes. The study compares APS patients to healthy individuals by taking blood samples to measure the expression of ANXA2 and its partner protein S100A10 on monocytes using flow cytometry. The main focus is on the amount of ANXA2 on the cell membrane, which may influence plasmin generation, an important factor in blood clot regulation. This is a non-randomized, interventional study involving blood withdrawal as the intervention. Participants will have blood collected for analysis during a one-hour visit. Researchers will examine the levels of ANXA2 and S100A10 on monocytes to assess their involvement in APS. The primary outcome is the rate of ANXA2 expression on monocytes. Secondary outcomes include cellular expression levels of both proteins. The study is sponsored by Centre Hospitalier Universitaire, Amiens, and expects to end in March 2026.
CONDITIONS
Brief Title
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Research Team
V
Valéry Salle, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here